10.16.25 -- Your Partners In Cell & Gene Therapy Innovation

Join 1,000+ pharma, biotech, and drug delivery professionals at the PODD: Partnership Opportunities in Drug Delivery Conference conference, October 27–28 in Boston. Featuring 10 technology tracks, pharma company spotlights, 1:1 partnering, and more. Attendees will also hear from leaders at companies including AbbVie, Amgen, AstraZeneca, Biogen, Eli Lilly, GSK, Moderna, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, and others. Register at PODDConference.com with code LSL20 for 20% off.

Whether your therapy relies on viral delivery systems like AAV, lentivirus, or cutting-edge gene editing technologies, we provide comprehensive lab testing support throughout development.

As a CDMO Partner for Life™, our goal is to advance your cell therapies from lab to commercial scale, leveraging our cell and gene therapy expertise and global cGMP network.

Explore how proprietary cell lines enhance development, reduce costs, and accelerate market entry with built-in regulatory support and extensive expertise in adherent cell culture.

Confidently navigate every stage of development with tailored tech transfer solutions backed by AAV expertise. Discover how to de-risk, scale, and optimize your process for high-quality performance.

Our robust analytical capabilities support development processes and ensure our products are well characterized, safe and meet regulatory guidelines.

The 362M two-sided labeling machine brings precision and versatility to your production line. This high-speed workhorse labels up to 200 products per minute, even those with challenging shapes.

Here, we describe how expert CMC strategies and clinical manufacturing experience can lay the groundwork for the successful commercialization of advanced cell therapies.

Ready to go deeper on cell characterization? Advance past typical cell and donor screening to create a comprehensive immune cell profile for each donor and more.

The streamlined AAV transient transfection platform de-risks your path to IND and reduces complexity and timeline for lengthy process and analytical development.